Trial Profile

The global Phase III clinical study of JHL1149 in patients with non-small cell lung cancer (NSCLC)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Eden Biologics

Most Recent Events

16 Oct 2018 National Medical Products Administration of the PRC (NMPA) has approved Phase I and Phase III Clinical Trial Application for JHL1149.
23 Aug 2018 New trial record
09 Aug 2018 According to a JHL Biotech media release, the EMA confirmed it agrees with JHL's development approach, clinical development proposal and design of this phase 3 study. Based on the EMA's review of these factors, the results of the Phase III clinical study will be acceptable for the submission of a Marketing Authorization Application as a biosimilar product, assuming the Phase III trial is completed successfully.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com